Abstract Number: 2985 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database
Background/Purpose : SSc related PH carries a high mortality; with SSc-PH related to restrictive lung disease (RLD) having worse prognosis and more rapid time to…Abstract Number: 845 • 2015 ACR/ARHP Annual Meeting
Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension
Background/Purpose: The majority of published models for prediction of PH use cross-sectional data, while studies exploring the use of repeated measurements of lung function tests…Abstract Number: 1077 • 2015 ACR/ARHP Annual Meeting
High Levels of CCL-18 Are Associated with Deterioration of Lung Function, Increased Annual Fibrosis Progression Rate and Decreased Survival in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but biomarkers for individual risk stratification are largely missing. There is an…Abstract Number: 1504 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thromboembolism Among Patients with VTE Association with Rheumatoid Arthritis
Increased risk of thromboembolism among patients with VTE association with Rheumatoid Arthritis Background/Purpose: Rheumatoid arthritis (RA), is among most common autoimmune conditions manifested by progressive and…Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting
Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…Abstract Number: 1691 • 2014 ACR/ARHP Annual Meeting
Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients with systemic sclerosis (SSc). Transthoracic echocardiogram and pulmonary function testing are standard noninvasive…Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…Abstract Number: 734 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Background/Purpose Lower socioeconomic status (SES) and male gender have been associated with worse survival in idiopathic pulmonary arterial hypertension (PAH). Pulmonary Hypertension Assessment and Recognition…Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…Abstract Number: 2588 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of morbidity and mortality in patients with connective tissue diseases (CTD). Patients with anti-U1-RNP antibodies belong to…Abstract Number: 2591 • 2013 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient
Background/Purpose: Systemic Sclerosis (SSc) is associated with occlusive vasculopathy resulting in digital ischaemia, telangiectasia, scleroderma renal crisis (SRC) and pulmonary arterial hypertension (PAH). SRC and…Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…Abstract Number: 720 • 2012 ACR/ARHP Annual Meeting
Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis
Background/Purpose: Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in systemic sclerosis (SSc). Pulmonary arterial hypertension (PAH) is reportedly the most frequent…Abstract Number: 721 • 2012 ACR/ARHP Annual Meeting
Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis
Background/Purpose: Pulmonary hypertension (PH) is a major complication of systemic sclerosis (SSc). We observed that a significant proportion of our SSc patients with PH as…
ACR Meeting Abstracts